MCID: CHL028
MIFTS: 55

Childhood Type Dermatomyositis

Categories: Rare diseases, Skin diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Muscle diseases

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 37 12 14
Juvenile Dermatomyositis 12 72 49 55 69
Dermatomyositis, Childhood Type 69
Childhood Dermatomyositis 12
Juvenile Myositis 49
Juvenile Dm 55
Jdm 49
Jpm 49

Characteristics:

Orphanet epidemiological data:

55
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



Summaries for Childhood Type Dermatomyositis

NIH Rare Diseases : 49 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema, muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures. Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected.  About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements. Last updated: 7/25/2016

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to dermatomyositis and myositis, and has symptoms including dry skin, skin rash and pruritus. An important gene associated with Childhood Type Dermatomyositis is DMBX1 (Diencephalon/Mesencephalon Homeobox 1). The drugs Abatacept and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and heart.

Wikipedia : 72 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 dermatomyositis 29.6 IFIH1 MORC3
2 myositis 10.1
3 autoimmune disease of gastrointestinal tract 10.0 HLA-DQA1 TNFRSF25
4 type 1 diabetes mellitus 17 10.0 TNFRSF25 VWF
5 diabetes mellitus, insulin-dependent 9.9 HLA-DQA1 IFIH1 TNFRSF25
6 immune system disease 9.7 TNFRSF25 VWF
7 fibrodysplasia ossificans progressiva 9.6
8 calcinosis 9.6

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

55 31 (show all 46)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dry skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0000958
2 skin rash 55 31 hallmark (90%) Very frequent (99-80%) HP:0000988
3 pruritus 55 31 frequent (33%) Frequent (79-30%) HP:0000989
4 cutaneous photosensitivity 55 31 frequent (33%) Frequent (79-30%) HP:0000992
5 poikiloderma 55 31 frequent (33%) Frequent (79-30%) HP:0001029
6 muscular hypotonia 55 31 frequent (33%) Frequent (79-30%) HP:0001252
7 dysarthria 55 31 occasional (7.5%) Occasional (29-5%) HP:0001260
8 muscle weakness 55 31 hallmark (90%) Very frequent (99-80%) HP:0001324
9 arthritis 55 31 frequent (33%) Frequent (79-30%) HP:0001369
10 limitation of joint mobility 55 31 occasional (7.5%) Occasional (29-5%) HP:0001376
11 alopecia 55 31 frequent (33%) Frequent (79-30%) HP:0001596
12 hoarse voice 55 31 occasional (7.5%) Occasional (29-5%) HP:0001609
13 dysphonia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001618
14 cardiomyopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0001638
15 angina pectoris 55 31 occasional (7.5%) Occasional (29-5%) HP:0001681
16 pericarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001701
17 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
18 fever 55 31 frequent (33%) Frequent (79-30%) HP:0001945
19 dysphagia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002015
20 constipation 55 31 frequent (33%) Frequent (79-30%) HP:0002019
21 abdominal pain 55 31 occasional (7.5%) Occasional (29-5%) HP:0002027
22 dyspnea 55 31 occasional (7.5%) Occasional (29-5%) HP:0002094
23 pulmonary fibrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0002206
24 gastrointestinal hemorrhage 55 31 occasional (7.5%) Occasional (29-5%) HP:0002239
25 vasculitis 55 31 frequent (33%) Frequent (79-30%) HP:0002633
26 arthralgia 55 31 frequent (33%) Frequent (79-30%) HP:0002829
27 autoimmunity 55 31 hallmark (90%) Very frequent (99-80%) HP:0002960
28 elevated serum creatine phosphokinase 55 31 hallmark (90%) Very frequent (99-80%) HP:0003236
29 myalgia 55 31 hallmark (90%) Very frequent (99-80%) HP:0003326
30 muscle cramps 55 31 frequent (33%) Frequent (79-30%) HP:0003394
31 emg abnormality 55 31 occasional (7.5%) Occasional (29-5%) HP:0003457
32 elevated erythrocyte sedimentation rate 55 31 hallmark (90%) Very frequent (99-80%) HP:0003565
33 calcinosis 55 31 hallmark (90%) Very frequent (99-80%) HP:0003761
34 erythema 55 31 hallmark (90%) Very frequent (99-80%) HP:0010783
35 elevated c-reactive protein level 55 31 hallmark (90%) Very frequent (99-80%) HP:0011227
36 arrhythmia 55 31 occasional (7.5%) Occasional (29-5%) HP:0011675
37 bundle branch block 55 31 occasional (7.5%) Occasional (29-5%) HP:0011710
38 fatigue 55 31 hallmark (90%) Very frequent (99-80%) HP:0012378
39 cough 55 31 occasional (7.5%) Occasional (29-5%) HP:0012735
40 palpebral edema 55 31 hallmark (90%) Very frequent (99-80%) HP:0100540
41 mucosal telangiectasiae 55 31 hallmark (90%) Very frequent (99-80%) HP:0100579
42 telangiectasia of the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0100585
43 myositis 55 31 hallmark (90%) Very frequent (99-80%) HP:0100614
44 skin ulcer 55 31 frequent (33%) Frequent (79-30%) HP:0200042
45 restrictive lung disease 55 Frequent (79-30%)
46 restrictive ventilatory defect 31 frequent (33%) HP:0002091

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3 332348-12-6 10237
2 Antirheumatic Agents Phase 4,Phase 3,Phase 2
3 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
4 Hormone Antagonists Phase 4,Phase 3,Phase 2
5 Hormones Phase 4,Phase 3,Phase 2
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
7 Vaccines Phase 4
8 Adrenocorticotropic Hormone Phase 4
9 beta-endorphin Phase 4
10 Melanocyte-Stimulating Hormones Phase 4
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
12
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
13
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
16
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
17
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
18
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
21 Antiemetics Phase 3,Phase 2
22 Antifungal Agents Phase 3
23 Anti-Infective Agents Phase 3,Phase 2
24 Anti-Inflammatory Agents Phase 3,Phase 2
25 Antimetabolites Phase 3,Phase 2
26 Antimetabolites, Antineoplastic Phase 3,Phase 2
27 Antineoplastic Agents, Hormonal Phase 3,Phase 2
28 Autonomic Agents Phase 3,Phase 2
29 Calcineurin Inhibitors Phase 3
30 Cyclosporins Phase 3
31 Dermatologic Agents Phase 3,Phase 2
32 Folic Acid Antagonists Phase 3,Phase 2
33 Gastrointestinal Agents Phase 3,Phase 2
34 glucocorticoids Phase 3,Phase 2
35 Methylprednisolone acetate Phase 3,Phase 2
36 Methylprednisolone Hemisuccinate Phase 3,Phase 2
37 Neuroprotective Agents Phase 3,Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 3,Phase 2
40 Prednisolone acetate Phase 3,Phase 2
41 Prednisolone hemisuccinate Phase 3,Phase 2
42 Prednisolone phosphate Phase 3,Phase 2
43 Protective Agents Phase 3,Phase 2
44 Vitamin B Complex Phase 3,Phase 2
45 Bone Density Conservation Agents Phase 2, Phase 3
46 Analgesics Phase 2, Phase 3
47 Analgesics, Non-Narcotic Phase 2, Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
49 Folate Nutraceutical Phase 3,Phase 2
50 Vitamin B9 Nutraceutical Phase 3,Phase 2

Interventional clinical trials:

(show all 21)

# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
5 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
6 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
7 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
8 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
9 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
10 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
11 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
12 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320
13 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Unknown status NCT02267005
14 Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Completed NCT00001973
15 The CARRA Registry Completed NCT01697254
16 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
17 Juvenile Dermatomyositis Recruiting NCT03433638
18 Incidence and Prevalence of Juvenile Dermatomyositis Recruiting NCT03432455
19 Adult and Juvenile Myositis Recruiting NCT00017914
20 Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes Available NCT01724580 Baricitinib
21 Yellow Fever Vaccine in Patients With Rheumatic Diseases Not yet recruiting NCT03430388

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

38
Skeletal Muscle, Skin, Heart, Bone, Lung

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 225)
# Title Authors Year
1
Extensive skin ulcers in a child with juvenile dermatomyositis. ( 29367373 )
2018
2
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. ( 29361142 )
2018
3
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. ( 29373707 )
2018
4
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. ( 29342499 )
2018
5
Juvenile Dermatomyositis: Key Roles of Muscle Magnetic Resonance Imaging and Early Aggressive Treatment. ( 28911766 )
2017
6
A case of lipoatrophic diabetes induced by juvenile dermatomyositis. ( 28895299 )
2017
7
Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis. ( 28957546 )
2017
8
Race and income affects outcomes in juvenile dermatomyositis. ( 28434566 )
2017
9
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. ( 28977549 )
2017
10
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
11
Recurrence of juvenile dermatomyositis 8A years after remission. ( 28050594 )
2017
12
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. ( 28073708 )
2017
13
Myogenic progenitor cells exhibit IFN type I-driven pro-angiogenic properties and molecular signature during juvenile dermatomyositis. ( 28941175 )
2017
14
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). ( 28934971 )
2017
15
Juvenile dermatomyositis: a tertiary center experience. ( 28058540 )
2017
16
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. ( 28077146 )
2017
17
Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. ( 28448730 )
2017
18
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. ( 28514969 )
2017
19
Focal hyperkeratosis overlying the palmar faces of interphalangeal and metacarpophalangeal joints revealing a juvenile dermatomyositis. ( 28895209 )
2017
20
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. ( 27606477 )
2016
21
Calcinosis in juvenile dermatomyositis mimicking cold abscess. ( 27586213 )
2016
22
MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis. ( 26628598 )
2016
23
Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making. ( 27650736 )
2016
24
Improvement of nailfold capillary microangiopathy after immunosuppressant therapy in a child with clinically amyopathic juvenile dermatomyositis. ( 27157691 )
2016
25
Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work. ( 26971888 )
2016
26
Muscle biopsy in combination with myositis-specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis. ( 27214289 )
2016
27
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. ( 27155307 )
2016
28
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. ( 27588444 )
2016
29
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. ( 27623619 )
2016
30
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. ( 27007612 )
2016
31
Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. ( 25800510 )
2015
32
Efficacy and safety of creatine supplementation in juvenile dermatomyositis: A randomized double-blind placebo-controlled cross-over trial. ( 25899989 )
2015
33
Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis. ( 26472413 )
2015
34
Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. ( 26493816 )
2015
35
Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. ( 26493320 )
2015
36
In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset. ( 26500284 )
2015
37
A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma. ( 26489640 )
2015
38
Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis. ( 26203832 )
2015
39
Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. ( 26581448 )
2015
40
Radiographic patterns of soft tissue calcinosis in juvenile dermatomyositis and its clinical implications. ( 25654011 )
2014
41
Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. ( 25288783 )
2014
42
Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. ( 24397895 )
2014
43
Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. ( 25157414 )
2014
44
Acute acalculous cholecystitis in a patient with juvenile dermatomyositis. ( 25239990 )
2014
45
Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. ( 23839717 )
2014
46
Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis. ( 24789670 )
2014
47
Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. ( 24647150 )
2014
48
Unrecognized juvenile dermatomyositis complicated by calcinosis universalis: a case report from Cameroon. ( 24401174 )
2014
49
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. ( 25366934 )
2014
50
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. ( 23636654 )
2013

Variations for Childhood Type Dermatomyositis

Expression for Childhood Type Dermatomyositis

LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Pathways for Childhood Type Dermatomyositis

GO Terms for Childhood Type Dermatomyositis

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein sumoylation GO:0016925 8.62 IFIH1 SAE1

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 single-stranded RNA binding GO:0003727 8.62 IFIH1 SNRPC

Sources for Childhood Type Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....